EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Factors Associated With Mineralocorticoid Receptor Antagonist Initiation in Newly Diagnosed Heart Failure

Gregg C Fonarow, Carolyn S P Lam, Alanna A Morris, Yik Ming Fung, Zihe Zheng, Sonia Gomez, Katsiaryna Holl, Marco Antonio Lavagnino, Arvind Katta, Rachel Knapp

Journal of Cardiac Failure · 2026-10

DOI: 10.1016/j.cardfail.2026.09.025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiac Failure, 2026-10. Verfasst von Gregg C Fonarow und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles Medical Center, Los Angeles, California. Electronic ad…. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer, Pharmaceuticals Bayer, Bayer HealthCare Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) is increasingly recognized within the broader context of cardiovascular-kidney-metabolic (CKM) syndrome, characterized by the interrelationship of excess adiposity, metabolic dysfunction, chronic kidney disease (CKD), and cardiovascular disease.1 The ability to initiate and maintain guideline-directed medical therapy (GDMT) may be particularly affected by the intersection of CKD and HF. Steroidal mineralocorticoid receptor antagonist (sMRA) remains among the least prescribed GDMT classes across the ejection fraction (EF) spectrum, possibly due to reported risks of worsening kidney function, hyperkalemia, and failure to demonstrate improvements in cardiovascular outcomes, especially among those with CKD.

Schlagwörter

Stichwörter der Autor:innen

Cardiovascular–kidney–metabolicheart failuremineralocorticoid receptor antagonisttime-to-treatment

Autor:innen und Institutionen

  • Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles Medical Center, Los Angeles, California. Electronic address: gfonarow@mednet.ucla.edu.
  • National Heart Centre Singapore & Duke-National University of Singapore Medical School, Singapore.
  • Bayer US, Whippany, New Jersey.
  • Bayer AG, Berlin, Germany.
  • Bayer US, Whippany, New Jersey; Syneos Health, Morrisville, North Carolina.

Förderung

  • Bayer
  • Pharmaceuticals Bayer
  • Bayer HealthCare Pharmaceuticals Inc

Zitieren

APA

Fonarow, G. C., Lam, C. S. P., Morris, A. A., Fung, Y. M., Zheng, Z., Gomez, S., Holl, K., Lavagnino, M. A., Katta, A., & Knapp, R. (2026). Factors Associated With Mineralocorticoid Receptor Antagonist Initiation in Newly Diagnosed Heart Failure. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2026.09.025

Vancouver

Fonarow GC, Lam CSP, Morris AA, Fung YM, Zheng Z, Gomez S, et al. Factors Associated With Mineralocorticoid Receptor Antagonist Initiation in Newly Diagnosed Heart Failure. Journal of Cardiac Failure. 2026. doi:10.1016/j.cardfail.2026.09.025

BibTeX
@article{Fonarow2026,
  author = {Fonarow, Gregg C and Lam, Carolyn S P and Morris, Alanna A and Fung, Yik Ming and Zheng, Zihe and Gomez, Sonia and Holl, Katsiaryna and Lavagnino, Marco Antonio and Katta, Arvind and Knapp, Rachel},
  title = {Factors Associated With Mineralocorticoid Receptor Antagonist Initiation in Newly Diagnosed Heart Failure},
  journal = {Journal of Cardiac Failure},
  year = {2026},
  doi = {10.1016/j.cardfail.2026.09.025}
}
Kostenlos starten →